详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The landscape of N6-methyladenosine in localized primary prostate cancer

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 自然指数

作者：

机构： [1]Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. [2]Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [3]Vector Institute, Toronto, Ontario, Canada. [4]Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA. [5]Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA. [6]Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, CA, USA. [7]Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA. [8]Department of Chemistry, the University of Chicago, Chicago, IL, USA. [9]Howard Hughes Medical Institute, the University of Chicago, Chicago, IL, USA. [10]Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. [11]Sunnybrook Research Institute, Toronto, Ontario, Canada. [12]MOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China. [13]Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. [14]Research Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada. [15]State Key Laboratory of Common Mechanism Research for Major Disease, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Suzhou, China. [16]Division of Cancer Sciences, University of Manchester, Manchester, UK. [17]Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK. [18]Geneseeq Research Institute, Geneseeq Technology lnc., Toronto, Ontario, Canada. [19]School of Public Health, Nanjing Medical University, Nanjing, China. [20]Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. [21]West China School of Public Health, West China Fourth Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China. [22]Institute of Precision Medicine, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. [23]Department of Respiratory and Critical Care Medicine, the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China.

出处：

DOI：

ISSN：

摘要：

N6-methyladenosine (m6A), the most abundant internal RNA modification in humans, regulates most aspects of RNA processing. Prostate cancer is characterized by widespread transcriptomic dysregulation; therefore, we characterized the m6A landscape of 162 localized prostate tumors with matched DNA, RNA and protein profiling. m6A abundance varied dramatically across tumors, with global patterns emerging via complex germline-somatic cooperative regulation. Individual germline polymorphisms regulated m6A abundance, cooperating with somatic mutation of cancer driver genes and m6A regulators. The resulting complex patterns were associated with prognostic clinical features and established the biomarker potential of global and locus-specific m6A patterns. Tumor hypoxia dysregulates m6A profiles, bridging prior genomic and proteomic observations. Specific m6A sites, such as those in VCAN, drive disease aggression, associating with poor outcomes, tumor growth and metastasis. m6A dysregulation is thus associated with key events in the natural history of prostate cancer: germline risk, microenvironmental dysregulation, somatic mutation and metastasis.© 2025. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 1 区

生物学

小类 | 1 区遗传学

最新[2025]版：

大类 | 1 区

生物学

小类 | 1 区遗传学

第一作者：

第一作者机构： [1]Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.

共同第一作者：

通讯作者：

通讯机构： [1]Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. [2]Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [3]Vector Institute, Toronto, Ontario, Canada. [4]Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA. [5]Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA. [6]Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, CA, USA. [7]Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA. [20]Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

推荐引用方式(GB/T 7714)：

APA：

MLA：